NIPH Clinical Trials Search

Basic Information

Recruitment status	completed
Health condition(s) or Problem(s) studied
Date of first enrollment	01/11/2018
Target sample size	732
Countries of recruitment	Japan,Asia except Japan,North America,South America,Europe,Oceania,Africa
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : INN of investigational material : Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcome	efficacy efficacy
Secondary Outcome	efficacy safety efficacy safety

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria
Exclude criteria